With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

For this review, the authors searched for randomized controlled trials published in MEDLINE, Embase, and Cochrane CENTRAL ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

Diet food brands have been hit in recent years, but now GLP-1 drugs like Ozempic are hitting the market, will this spell the ...

Research showed that patients who lose weight on GLP-1 agonists frequently experience muscle mass loss. Obesity experts share ...

A nationwide study confirms GLP-1 RAs pose no short-term psychiatric risk, showing a negative association with suicidal ...

A systematic review of randomized controlled trials (RCTs) assessed the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and co-agonists for obesity in adults without ...

Expanding volumes of data point to mechanisms beyond weight loss and blood sugar control that contribute to cardiovascular ...

Results showed patients with a BMI of 40 kg/m2 or more who used glucagon-like peptide-1 receptor agonists for at least 90 ...

GLP-1 receptor agonists (GLP-1RAs) on multiple fronts. They continued to expand into new indications, and provide their developers with both rich remuneration and scientific acclamation. There are now ...

John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors.